|
|
|
17.06.25 - 22:09
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $21.98 per share, Acadia's closing trading price on June 6, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The RSUs...
|
|
|
|
|
27.05.25 - 22:09
|
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio.
“We are delighted to welcome Allyson to Acadia,” said Catherine Owen Adams, Chief Executive Officer. “She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders—as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need.”
Allyson's distinguished car...
|
|
|
20.05.25 - 22:09
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 64,252 shares of common stock and 56,277 restricted stock units (“RSUs”) to twenty-eight new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $14.81 per share, Acadia's closing trading price on May 7, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The RSUs...
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.25 - 15:03
|
ERMA Systems Appoints Christine Hendrick, Director of Commercial Services, to Advisory Board (Business Wire)
|
|
|
MIAMI--(BUSINESS WIRE)--ERMA Systems, a leading provider of intelligent MLR (Medical, Legal, and Regulatory) management solutions for the life sciences sector, is pleased to announce the appointment of Christine Hendrick, currently Director of Commercial Services at Acadia Pharmaceuticals Inc., to its Advisory Board.
With more than 15 years of experience in commercial operations, product launch, and strategic planning within the pharmaceutical industry, Christine brings a wealth of expertise to the development of ERMA Evaluate™. Throughout her career she has overseen product commercialization efforts and led multiple companies' MLR process—insights that align closely with ERMA's mission to streamline and elevate how life sciences companies manage and optimize these critical workflows.
"Christine's deep knowledge at the intersection of commercial execution and MLR processes makes her an exceptional addition to our advisory board," said Julia Gardner, CEO of ERMA Systems. "Her leadersh...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.04.25 - 22:06
|
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 (Business Wire)
|
|
|
Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time.
The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize...
|
|
|
11.04.25 - 22:06
|
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $16.12 per share, Acadia's closing trading price on April 3, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The R...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
